Redeye provides its brief comments on Ngenic’s Q4 report, which was better than expected.
Björn Borg (“Björn Borg”, “the Company” or “the Group”) is a well-established and renowned company w...
Redeye shares its initial thoughts on Dala Energi’s Q4 report, where the main highlight of the quart...
Aixias omsättning steg med 75% till 48 (27,4) mkr i det fjärde kvartalet, men rörelseresultatet uppg...
Redeye provides its initial take on Heliospectra’s Q4 results, noting that while sales were below ex...
Redeye provides a research update following the Q4 report published by Initiator Pharma earlier toda...
EBITDA 25% above driven by lower marketing costs Reiterates launch of Doro pre-installed sim cards i...
Redeye makes some revisions based on the Q4 report.
Redeye comments on FluoGuide’s Q4 2024 report. The company is approaching the interim readout of its...
Redeye comments on MindArk’s Q4 results, which came in softer than expected across the board.
Redeye comments on Maximum Entertainment’s Q4-results where topline came in somewhat softer than exp...
Orders +41%, sales +0%, adj. EBITA +12% vs. ABGSCe High NRIs lower quality of beat, but orders indic...
Group net sales was EUR 28.8m in Q4 (Nordea est. EUR 29.
Redeye is initiating coverage of Insplorion, a sensor technology company focusing on hydrogen detect...
Solwers had already released a profit warning for Q4 2024 and the full year on 1 February.
For Q4, we expect the gradual volume and price improvement to continue, while variable costs could d...
Redeye comments on WntResearch’s Q4 2024 report. The report was undramatic, which was expected in ou...
STENOCARE A/S (STENOCARE or the “Company”) published on February 27th the Company’s Q4-report for 20...
Addlife ökade omsättningen med 11% under fjärde kvartalet 2024, organisk tillväxt exklusive valutapå...
Luxbright AB (”Luxbright” eller ”Bolaget”) har stängt böckerna för helåret 2024, ett år präglat av e...
